Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Researchers Train Model to Identify Breast Lesions

By MedImaging International staff writers
Posted on 24 Oct 2017
Researchers have trained a machine-learning tool to identify high-risk, biopsy-diagnosed breast cancer lesions that are unlikely to become cancerous, and do not require immediate surgery.

The model was 97% accurate in its predictions and could help reduce unnecessary breast cancer surgeries by 33%. High-risk lesions have a higher risk of developing into cancer, but many such lesions could be safely monitored using imaging, without requiring surgery.

The study was published online in the October 2017 issue of the journal Radiology by researchers from Massachusetts Institute of Technology (MIT; Boston, MA, USA), and Massachusetts General Hospital (MGH; Boston, MA, USA). The machine-learning tool enabled the researchers to find those high-risk lesions that have a low risk of being upgraded to cancer.

The model took account of patient age, lesion histology, and other standard risk factors, but also included keywords from biopsy pathology reports. The researchers trained the model using patients with biopsy-proven high-risk lesions. After training the model on two-thirds of the high-risk lesions, the researchers found that they were able to identify 97% of the lesions that were upgraded to cancer. The researchers also found that by using the model they could help avoid almost one-third of the surgeries of benign tumors.

The author of the study, radiologist Manisha Bahl, MD, MPH, from MGH and Harvard Medical School, said, "There are different types of high-risk lesions. Most institutions recommend surgical excision for high-risk lesions such as atypical ductal hyperplasia, for which the risk of upgrade to cancer is about 20%. For other types of high-risk lesions, the risk of upgrade varies quite a bit in the literature, and patient management, including the decision about whether to remove or survey the lesion, varies across practices. Our goal is to apply the tool in clinical settings to help make more informed decisions as to which patients will be surveilled and which will go on to surgery."

Related Links:
Massachusetts Institute of Technology
Massachusetts General Hospital


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Thyroid Shield
Standard Thyroid Shield
Ultrasound System
Acclarix AX9
New
Pre-Op Planning Solution
Sectra 3D Trauma
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to MedImaging.net and get complete access to news and events that shape the world of Radiology.
  • Free digital version edition of Medical Imaging International sent by email on regular basis
  • Free print version of Medical Imaging International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of Medical Imaging International in digital format
  • Free Medical Imaging International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Ultrasound

view channel
Image: CAM figures of testing images (Photo courtesy of SPJ; DOI:10.34133/research.0319)

Diagnostic System Automatically Analyzes TTE Images to Identify Congenital Heart Disease

Congenital heart disease (CHD) is one of the most prevalent congenital anomalies worldwide, presenting substantial health and financial challenges for affected patients. Early detection and treatment of... Read more

Nuclear Medicine

view channel
Image: Researchers have identified a new imaging biomarker for tumor responses to ICB therapy (Photo courtesy of 123RF)

New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy

Immunotherapies, such as immune checkpoint blockade (ICB), have shown promising clinical results in treating melanoma, non-small cell lung cancer, and other tumor types. However, the effectiveness of these... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.